Skip to content

Database / VK2735

In Phase 3GIP/GLP-1 dual agonistInjection (oral in development) · Weekly

VK2735

No brand yet · Viking Therapeutics. A tirzepatide-like dual agonist from an independent biotech. 14.7% weight loss in just 13 weeks. Phase 3 VANQUISH trials are fully enrolled, 78 weeks long.

Average weight loss
14.7%
Stopped for side effects
n/r
Trial length
13 wk
Ranking score
n/r

VENTURE results

Phase 2 · 13 weeks · Up to 15 mg weekly
Adults with obesity

Weight loss
14.7%
Nausea
n/r
Vomiting
n/r
Diarrhea
n/r
Constipation
n/r
Quit due to side effects
n/r

n/r = not reported.

Worth knowing

  • Oral version: up to 12.2% weight loss at 13 weeks; oral Phase 3 expected to start Q4 2026.
  • 13-week results cannot be compared directly with 72-week trials.

Next catalysts

Q4 2026 Oral VK2735 Phase 3 program starts (Company guidance)

2027 VANQUISH Phase 3 trials complete (Trial estimate)

–
Not yet ranked
Needs Phase 3 data. We rank only drugs with a completed Phase 3 trial and published side-effect rates.

At a glance

Company
Viking Therapeutics
Targets
GLP-1, GIP
Molecule
Peptide
Dosing
Injection (oral in development), weekly
Status
In Phase 3

Compare with another drug

Sources

How VK2735 might compare in Phase 3

Projection · not reported data

Bar chart comparing projected VK2735 17.5 mg with retatrutide 12 mg and tirzepatide 15 mg on weight loss, nausea, vomiting, diarrhea, constipation, dysesthesia and discontinuation
Our projection, not trial data. VK2735 figures are estimates ahead of the VANQUISH Phase 3 results; its dysesthesia rate is an assumption because Viking has not disclosed one. Retatrutide: TRIUMPH-1, 80 weeks. Tirzepatide: SURMOUNT-1, 72 weeks. VK2735 is not ranked in the index until Phase 3 data are published.